A Phase 3, Long-Term, Open-Label Safety Study of Self-Administered Galcanezumab Injections in Patients with Migraine

被引：0
|
作者：
Stauffer, Virginia L. [1 ]
Sides, Ryan [1 ]
Camporeale, Angelo [1 ]
Skljarevski, Vladimir [1 ]
Ahl, Jonna [1 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PO-01-184
引用
收藏
页码：330 / 331
页数：2
相关论文
共 50 条
  • [1] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Angelo Camporeale
    David Kudrow
    Ryan Sides
    Shufang Wang
    Annelies Van Dycke
    Katherine J. Selzler
    Virginia L. Stauffer
    BMC Neurology, 18
  • [2] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Camporeale, Angelo
    Kudrow, David
    Sides, Ryan
    Wang, Shufang
    Van Dycke, Annelies
    Selzler, Katherine J.
    Stauffer, Virginia L.
    BMC NEUROLOGY, 2018, 18
  • [3] A long-term open-label safety study of galcanezumab in Japanese patients with migraine
    Hirata, Koichi
    Takeshima, Takao
    Sakai, Fumihiko
    Tatsuoka, Yoshihisa
    Suzuki, Norihiro
    Igarashi, Hisaka
    Nakamura, Tomomi
    Ozeki, Akichika
    Yamazaki, Hiroyoshi
    Skljarevski, Vladimir
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 721 - 733
  • [4] Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache
    Riesenberg, Robert
    Gaul, Charly
    Stroud, Chad E.
    Dong, Yan
    Bangs, Mark E.
    Wenzel, Richard
    Martinez, James M.
    Oakes, Tina Myers
    CEPHALALGIA, 2022, 42 (11-12) : 1225 - 1235
  • [5] Patient Functioning and Disability among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
    McAllister, Peter
    Ford, Janet H.
    Stauffer, Virginia L.
    Sexson, Matthew
    Ayer, David
    Wang, Shufang
    NEUROLOGY, 2020, 94 (15)
  • [6] Patient Functioning and Disability Among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
    McAllister, P.
    Ford, J.
    Stauffer, V
    Sexson, M.
    Ayer, D.
    Wang, S.
    HEADACHE, 2019, 59 : 99 - 100
  • [7] Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
    Ford, Janet H.
    Stauffer, Virginia L.
    McAllister, Peter
    Akkala, Sreelatha
    Sexson, Matthew
    Ayer, David W.
    Wang, Shufang
    QUALITY OF LIFE RESEARCH, 2021, 30 (02) : 455 - 464
  • [8] PATIENT-REPORTED EXPERIENCES WITH SELF-INJECTIONS USING PREFILLED SYRINGE AND AUTOINJECTOR DEVICES IN AN OPEN-LABEL, LONG-TERM STUDY OF GALCANEZUMAB IN PATIENTS WITH MIGRAINE
    Stauffer, V. L.
    Sides, R.
    Lanteri-Minet, M.
    Kielbasa, W.
    Jin, Y.
    Selzler, K. J.
    Tepper, S. J.
    CEPHALALGIA, 2018, 38 : 93 - 94
  • [9] Patient-reported Experiences with Self-injections Using Prefilled Syringe and Autoinjector Devices in an Open-label, Long-term Study of Galcanezumab in Patients with Migraine
    Stauffer, V
    Sides, R.
    Kielbasa, W.
    Jin, Y.
    HEADACHE, 2018, 58 : 179 - 179
  • [10] Correction to: Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
    Janet H. Ford
    Virginia L. Stauffer
    Peter McAllister
    Sreelatha Akkala
    Matthew Sexson
    David W. Ayer
    Shufang Wang
    Quality of Life Research, 2021, 30 : 465 - 466
12345